In surprise, FDA adcomm votes unanimously in favor of bluebird's gene therapy for rare disease even with safety concerns - Endpoints News

6/9/2022 12:00:00 AM2 years 10 months ago
by Zachary Brennan

In the first day of a two-day meeting, the FDA's Cellular, Tissue and Gene Therapies advisory committee on Thursday gave a big thumbs up to bluebird bio's potential gene therapy for the rare but fatal condition known as cerebral adrenoleukodystrophy (CALD) by…

In the first day of a two-day meet­ing, the FDA’s Cel­lu­lar, Tis­sue and Gene Ther­a­pies ad­vi­so­ry com­mit­tee on Thurs­day gave a big thumbs up to blue­bird bio’s po­ten­tial gene ther­a­py for … [+5322 chars]

full article...